PATENT CLAIM ANALYSIS

Application Number: 15903671
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["514", "248000"]

Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Claim (Index 10):
The compound of  claim 2  having Formula (IIIb): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof, wherein:\n ring A is independently selected from phenyl and 5- to 6-membered heterocyclyl; \n G 1  is independently selected from aryl, C 3-6 cycloalkyl and 5- to 6-membered heterocyclyl, wherein said aryl, cycloalkyl and heterocyclyl are substituted with 1-4 R 8 ; \n G 2  is independently selected from N and CR 3b ; \n G 7  is independently selected from N and CR 3 ; \n G 8  is independently selected from N and CR 3 ; \n provided at least one of G 2 , G 7 , and G 8  is N; \n R 1  and R 2  are independently selected from H, halogen, CF 3 , C 1-6  alkyl, and hydroxyl; \n R 3  is independently selected from H, halogen, haloalkyl, C 1-4 alkyl (optionally substituted with R 6 ), C 2-4 alkenyl (optionally substituted with R 6 ), CN, NO 2 , \u2014(CH 2 ) n \u2014OR 5 , \u2014(CH 2 ) n \u2014NR 5 R 5 , \u2014(CH 2 ) n \u2014C(\u2550O)OR 5 , \u2014(CH 2 ) n \u2014NHC(\u2550O)OR 5 , \u2014(CH 2 ) n \u2014NHC(\u2550O)R 5 , \u2014(CH 2 ) n \u2014NHC(N\u2014CN)NHR 5 , \u2014(CH 2 ) n \u2014NHC(NH)NHR, \u2014(CH 2 ) n \u2014N\u2550CHNR 5 R 5 , \u2014(CH 2 ) n \u2014NHC(\u2550O)NR 5 R 5 , \u2014(CH 2 ) n \u2014C(\u2550O)NR 5 R 5 , \u2014(CH 2 ) n \u2014NHC(S)NR 9 C(\u2550O)R 5 , \u2014(CH 2 ) n \u2014S(\u2550O) p C 1-6  alkyl optionally substituted with R 11 , \u2014(CH 2 ) n \u2014S(\u2550O) p NR 5 R 5 , \u2014(CH 2 ) n \u2014NHS(\u2550O) p NR 5 R 5 , \u2014(CH 2 ) n \u2014NHS(\u2550O) p C 1-6  alkyl optionally substituted with R 11 , \u2014(CH 2 ) n \u2014C 3-10  carbocyclyl and \u2014(CH 2 ) n -4- to 10-membered heterocyclyl, wherein said carbocyclyl and heterocyclyl are optionally substituted with R 6 ; optionally, two adjacent R 3  groups on the carbocyclyl and heterocyclyl may form a ring optionally substituted with R 6 ; \n R 3a  is independently selected from H and halogen; \n R 3b  is independently selected from H, halogen, methyl, and CN; \n R 4  is independently selected from H, OH, F, Cl, Br, C 1-4  alkyl, C 1-4  alkoxy, CF 3 , CN, C 3-6  cycloalkyl, aryl, and 5- to 6-membered heterocyclyl, wherein said cycloalkyl, aryl and heterocyclyl are optionally substituted with R 6 ; \n R 5  is independently selected from H, C 1-4  alkyl (optionally substituted with halogen, hydroxyl, alkoxy, carboxy, alkoxycarbonyl, amino, substituted amino), \u2014(CH 2 ) n \u2014C 3-10  carbocyclyl and \u2014(CH 2 ) n -4- to 10-membered heterocyclyl, wherein said carbocyclyl and heterocyclyl are optionally substituted with R 6 ; \n R 6  is independently selected from \u2014(CH 2 ) n \u2014OH, \u2550O, NH 2 , \u2014(CH 2 ) n \u2014CN, halogen, C 1-6  alkyl, \u2014(CH 2 ) n \u2014C(\u2550O)OH, \u2014(CH 2 ) n \u2014C(\u2550O)OC 1-4  alkyl, \u2014(CH 2 ) n \u2014OC 1-4  alkyl, \u2014(CH 2 ) n \u2014C 3-6  cycloalkyl, \u2014(CH 2 ) n -4- to 10-membered heterocyclyl, and \u2014O\u2014(CH 2 ) n -4- to 10-membered heterocyclyl, wherein said cycloalkyl and heterocyclyl are optionally substituted with R 10 ; \n R 7  is independently selected from H, F, Cl, and methyl; \n R 8  is independently selected from H, halogen, CN, NH 2 , C 1-6  alkyl, haloalkyl, alkylcarbonyl, alkoxy, haloalkoxy, aryl, C 3-6  cycloalkyl, and 4- to 12-membered heterocyclyl, wherein said aryl, cycloalkyl, and heterocyclyl are optionally substituted with R 10 ; \n R 10  is independently selected from H, C 1-6  alkyl (optionally substituted with R 11 ), C 2-6  alkenyl, C 2-6  alkynyl, aryl, \u2014(CH 2 ) n \u2014C 3-6  cycloalkyl (optionally substituted with R 11 ), \u2014(CH 2 ) n \u2014O-4- to 10-membered heterocyclyl (optionally substituted with R 11 ), F, Cl, Br, CN, NO 2 , \u2550O, C(\u2550O)NR 12 R 12 , C(\u2550O)OR 12 , Si(C 1-4  alkyl) 3 , \u2014(CH 2 ) n \u2014OR 12 , \u2014(CH 2 ) n \u2014NR 12 R 12 , \u2014S(\u2550O) p C 1-6  alkyl, NR 12 S(\u2550O) p C 1-6  alkyl, and S(\u2550O) p NR 12 R 12 ; \n R 11 , at each occurrence, is independently selected from H, halogen, C 1-5  alkyl, \u2014(CH 2 ) n \u2014OH, C 3-6  cycloalkyl, and phenyl; \n R 12 , at each occurrence, is independently selected from H, C 1-5  alkyl, C 3-6  cycloalkyl, phenyl, and heterocyclyl, or R 12  and R 12  together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with C 1-4 alkyl; \n n, at each occurrence, is an integer independently selected from 0, 1, and 2; and \n p, at each occurrence, is an integer independently selected from 0, 1, and 2.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 88.0
- Lexical Diversity: 1.27778
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14872546', '15115314', '15747867', '15205059', '15735322']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8216285325355668
- 35 USC 102 Novelty (BERT): 0.6460286258387044
- Combined Prediction Score: 0.8040685418658806
- Mean Citation Score: 526.2841340000001
- Max Citation Score: 598.2743
- Similarity Product: 585.0417925403298

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test